KRAS Cancer Drugs Get Two FDA Breakthroughs

Two drugs targeting the same cancer mutation received FDA breakthrough therapy designations in March 2026 — a mutation that scientists spent 40 years calling impossible to treat. Revolution Medicines' daraxonrasib, which targets multiple KRAS variants in pancreatic cancer, and zoldonrasib, the first drug ever to earn breakthrough status specifically for the KRAS G12D mutation in lung cancer, mark the most concentrated progress against this single target in oncology history.

That matters because KRAS isn't rare. It's the most commonly mutated cancer gene in humans. About 3.4 million new cancer patients every year — roughly one in five — carry a RAS mutation driving their disease.

Four Decades of Failure

The KRAS protein was identified as a cancer driver in the early 1980s. What followed was one of the longest losing streaks in drug development. The protein's surface is almost perfectly smooth, with no obvious pocket where a small molecule could bind and shut it down. Generations of pharmaceutical chemists tried and failed. KRAS earned the nickname "undruggable," and for most of a career span in science, nobody proved otherwise.

The FDA's recent shift toward one-trial approvals makes the regulatory path faster — but the scientific challenge of KRAS was never about paperwork. It was about chemistry.

The first crack came in 2021 when sotorasib won FDA approval for a specific KRAS subtype called G12C, found in about 13% of lung cancers. That was a proof of concept: the undruggable target could, in fact, be drugged. But G12C is just one of many KRAS variants. The most common — G12D — drives 36% of pancreatic cancers, 12% of colorectal cancers, and a chunk of lung cancers. It remained untouched.

Until now.

The Numbers That Changed Everything

Revolution Medicines, a clinical-stage biotech company based in Redwood City, California, attacked the problem differently. Instead of waiting for the KRAS protein to switch off and then trapping it (the approach used by sotorasib), their drugs grab KRAS while it's still active — in its "on" state. The company calls these RAS(ON) inhibitors.

The results from daraxonrasib in second-line pancreatic cancer patients tell the story. Among 26 patients with KRAS G12X mutations treated at the Phase 3 dose of 300 mg daily:

• 35% confirmed objective response rate — their tumours measurably shrank
• 92% disease control rate — tumours stopped growing in nearly every patient
• 8.5 months median progression-free survival
• 13.1 months median overall survival

To understand why oncologists are paying attention, you need context. Pancreatic ductal adenocarcinoma is the most lethal common cancer. The five-year survival rate for metastatic pancreatic cancer is 3.2%. The current standard second-line chemotherapy delivers a median overall survival of about 6 months. Daraxonrasib more than doubled that to 13.1 months — as a single pill, once daily.

In first-line treatment (patients who hadn't received any prior therapy), the numbers were even stronger: a 47% response rate and 89% disease control rate across 38 patients.

The G12D Breakthrough

The second designation, announced this week, is arguably even more consequential. Zoldonrasib received FDA breakthrough therapy designation for KRAS G12D-mutated non-small cell lung cancer — the first time any drug targeting this specific mutation has earned that status.

"The breakthrough therapy designation for zoldonrasib — the first ever granted for an investigational drug specifically targeting the KRAS G12D mutation — underscores the significant unmet need for patients with KRAS G12D cancers, which currently lack any approved targeted therapies," said Mark A. Goldsmith, CEO of Revolution Medicines.

G12D is the most prevalent KRAS mutation across all cancer types. It's the dominant driver in pancreatic cancer, common in colorectal cancer, and present in lung cancer. Yet until the AACR Annual Meeting in San Diego earlier this month — where Revolution Medicines presented new Phase 1 data for zoldonrasib — no targeted therapy existed for it.

The company now has three RAS(ON) inhibitors in clinical development: daraxonrasib (multi-selective), zoldonrasib (G12D-selective), and elironrasib (G12C-selective). All three have received FDA breakthrough therapy designations. That kind of pipeline concentration on a single target, with all three drugs earning the agency's highest-urgency review pathway, is unusual in oncology.

Why This Isn't Just a Lab Story

The Hormuz blockade is emptying pharmacies worldwide, and the conversation about global health has understandably shifted toward supply chains and access. But drug discovery breakthroughs and supply chain crises are two halves of the same equation. A drug that doesn't exist can't be supplied, no matter how open the shipping lanes.

Pancreatic cancer killed an estimated 510,000 people globally in 2022. Lung cancer killed 1.8 million. For a large fraction of those patients, KRAS mutations drove their disease, and there was nothing targeted to offer them. The standard treatment — chemotherapy — poisons fast-growing cells indiscriminately and carries brutal side effects.

Targeted therapies work differently. They go after the specific molecular error driving the tumour. When they work, they tend to work with fewer side effects and longer responses. Revolution Medicines reported that daraxonrasib at the Phase 3 dose was "generally well tolerated" with no new safety signals, and patients maintained a mean dose intensity of 85% — meaning most patients could stay on the drug at full strength, which is unusual for cancer treatment.

The Access Question Nobody's Asking Yet

There's a gap in this story that will matter enormously in the next two years. KRAS mutations are universal across populations — they appear at similar rates in patients regardless of geography, ethnicity, or income. A farmer in Bihar with pancreatic cancer has roughly the same chance of carrying a KRAS G12D mutation as an executive in Manhattan.

But the drugs being developed to target those mutations are emerging entirely from US and European biotech companies, tested primarily in clinical trials at Western hospitals, priced for Western insurance markets.

The Phase 3 RASolute 302 trial for daraxonrasib in pancreatic cancer is currently enrolling globally, with results expected later in 2026. If it succeeds, the conversation will shift fast from "can we drug KRAS?" to "who gets access?"

That question is already urgent. India — which supplies over 60% of the world's generic medications — has no generic pathway for drugs that haven't been approved yet. China's own KRAS programs are running behind. And the countries with the highest pancreatic cancer mortality rates per capita include several in Eastern Europe and Central Asia where clinical trial infrastructure is thin.

What Comes Next

The immediate timeline: Revolution Medicines expects to complete enrollment of RASolute 302 this year, with a data readout in 2026 that could support regulatory submissions. A second Phase 3 trial, RASolute 303, is testing daraxonrasib as a first-line treatment in combination with chemotherapy — potentially making it the standard of care for newly diagnosed pancreatic cancer patients. A third trial, RASolute 304, is testing whether daraxonrasib can prevent recurrence after surgery.

For zoldonrasib, the breakthrough designation will accelerate regulatory interactions, but the drug is earlier in development. Phase 3 trials are being planned.

The bigger picture: after 40 years of "undruggable," the KRAS field has gone from zero approved therapies (pre-2021) to sotorasib and adagrasib (G12C-specific, approved 2021-2023) to three drugs with breakthrough designations covering G12C, G12D, and multi-selective variants. The pace is accelerating.

For the 3.4 million people diagnosed each year with RAS-mutated cancers, the question is no longer whether the science can reach them. It's whether the health systems, supply chains, and pricing structures of a fractured world can deliver it before they run out of time.